Trial Profile
A prospective, multicentre, observational, postmarketing surveillance study of tafluprost/timolol in patients with glaucoma and ocular hypertension
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Dec 2016
Price :
$35
*
At a glance
- Drugs Tafluprost/timolol (Primary)
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions; Therapeutic Use
- 28 Dec 2016 New trial record
- 01 Dec 2016 Interim results (n=439) from 3-months follow-up published in the Ophthalmology and Therapy.